Avalo Therapeutics AVTX AVTX-007 — Contingent consideration
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's avtx-007 — contingent consideration.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's AVTX-007 — contingent consideration?
- Avalo Therapeutics (AVTX) reported AVTX-007 — contingent consideration of $17.5M in Q1 2026.
- How has Avalo Therapeutics's AVTX-007 — contingent consideration changed year-over-year?
- Avalo Therapeutics's AVTX-007 — contingent consideration increased by 116.0% year-over-year, from $8.1M to $17.5M.
- What does AVTX-007 — contingent consideration mean?
- Captures the estimated fair value of future payments that are dependent on the occurrence of specified events, such as regulatory approvals or sales targets, related to the AVTX-007 asset. This metric reflects the company's liability for future performance-based obligations arising from acquisitions or licensing agreements. It is essential for assessing the long-term financial commitments tied to the success of the product.